Abstract
Antimicrobial activity, human pharmacokinetic properties and clinical efficacy of ceftazidizne (CAZ, SN401), a newly developed injectable cephalosporin, were evaluated and the following results were obtained.
1) Antimicrobial activity of CAZ against various clinically isolated strains was compared with that of ceftiam and cefmetazole. Though antimicrobial activity of CAZ against S. aureus was inferior to cefotiam and cefmetazole, against E. coli, K. pneumoniae, H. influenzae, P. mirabilis, indol positive proteus and S. marcescens, CAZ was more active than cefotiam and cefmetazole, with the peak MICs ranging 0.05-0.18μg/ml. CAZ was more active than any other cephalosporins against glucose nonfermentative gram-negative bacteria such as P. aeruginosa, P. cepacia and Acientohacter.
2) The peak serum levels of CAZ after 1-hour intravenous drip infusion of 1.0g were 65 and 71μg/ml (mean: 68μg/ml), and the mean urinary recovery up to 8 hours from the start of infusion was 91.2%.
3) A daily dose of 1.0-4.0g of CAZ was administered to 32 cases and an efficacy evaluation was made in 28 cases. Four cases responded excellently to CAZ treatment, 16 cases effectively, 4 cases fairly and 4 cases poorly. Skin eruption was observed in 1 case but there was neither other clinical side effect nor abnormal chagne in laboratory findings.
As a result, CAZ is considered to be a useful drug for the treatment of infectious diseases.
